Accordingly, in September 2022 and May 2025, laboratory tests were performed, including the assessment of ACE (which may be elevated in sarcoidosis), rheumatoid factor (RF), anti-CCP, ANA profile, AMA antibodies, ASMA antibodies, LKM antibodies, anti-neutrophil cytoplasmic antibodies including pANCA, cANCA and anti-dsDNA antibodies, all of which are used in the evaluation of autoimmune diseases. This evidence concerns the gene PRTN3 and sarcoidosis.